<DOC>
	<DOCNO>NCT01210911</DOCNO>
	<brief_summary>Pancreatic cancer patient one bad prognoses among cancer type 5 year survival rate le 5 % . Despite significant change last decade molecular knowledge disease , prognosis management pancreatic cancer remain unchanged . With advance molecular biology , new biologic agent erlotinib , add benefit conventional cytotoxic agent . There grow body literature suggest type 2 diabetes mellitus ( DM ) may associate development pancreatic cancer , association complex . Because various DM medication affect directly key factor mediate association DM pancreatic cancer , understand effect anti-diabetic therapy pancreatic cancer critical step fully characterize role type 2 DM development pancreatic cancer . Indeed , two epidemiologic study find diabetic patient treat metformin less likely develop cancer , treat insulin likely die various kind cancer . Not metformin ameliorate hyperglycemia hyperinsulinemia , associated adverse impact DM cancer , metformin also direct metabolic effect activation adenosine monophosphate-activated protein kinase ( AMPK ) . AMPK regulate many metabolic enzyme also inhibit mammalian target rapamycin ( mTOR ) pathway via phosphorylation stabilization tumor suppressor gene TSC2 . But intensive cross-talk various pathway . Inhibition phosphoinositide 3-kinase ( PI3K ) /Akt pathway , mTOR one effector proteins , instance may result escape via mitogen-activated protein kinase ( MAPK ) pathway vice verse . Indeed , epidermal growth factor receptor ( EGFR ) activation lead activation MAPK pathway PI3K pathway . Thus , since clear block one pathway always sufficient produce response presence activate pathway , best change success realize use combination agent inhibit separate pathway know critical survival tumour . In line observation , combine small molecule EGFR inhibition PI3K pathway metformin might account potential candidate combinatorial approach . Therefore , study , investigator want determine activity safety concurrent interruption MAPK PI3K pathways EGFR tyrosine kinase inhibitor erlotinib metformin , combine gemcitabine patient metastatic pancreatic cancer .</brief_summary>
	<brief_title>Metformin Combined With Chemotherapy Pancreatic Cancer</brief_title>
	<detailed_description>In phase II randomize , placebo control study , patient locally advance metastatic pancreatic cancer randomize treatment gemcitabine , erlotinib metformin , gemcitabine , erlotinib placebo . Gemcitabine dose 1000 mg/m2 ( iv , 30 minute ) give weekly , 3 week , follow one week without treatment . Erlotinib administer daily dose 100 mg least one hour 2 hour ingestion food . Metformin/ placebo administer dose 500 mg twice daily . If well tolerate dose increased 1000 mg twice daily second week .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Signed informed content obtain prior treatment Cytological histological confirm carcinoma pancreas Metastatic cancer Measurable lesion accord RECIST criterion ECOG/ WHO performance 02 Age &gt; 18 year Adequate renal function ( creatinine &lt; 150 µmol/L and/ creatinine clearance &gt; 60 ml/ L ) Adequate liver function ( bilirubin &lt; 1.5 time upper limit normal , ALAT ASAT &lt; 5.0 time upper limit normal case liver metastases &lt; 2.5 upper limit normal absence liver metastasis ) . Adequate bone marrow function ( WBC &gt; 3.0 x 10 9/L , platelet &gt; 100 x 10 9/L ) Mentally , physically , geographically able undergo treatment follow Clinical radiological evidence CNS metastases Pregnancy ( positive serum pregnancy test ) lactation Serious concomitant systemic disorder would compromise safety patient , discretion investigator Patients severe and/or uncontrolled medical condition : unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction ≤ 6 month prior randomization , serious uncontrolled cardiac arrhythmia uncontrolled diabetes define fast serum glucose &gt; 2X ULN . active uncontrolled severe infection . cirrhosis , chronic active hepatitis chronic persistent hepatitis severely impaired lung function Previous treatment erlotinib Previous treatment gemcitabine metastatic disease Previous treatment gemcitabine combine radiotherapy locally advanced pancreatic cancer within 6 month prior study entry Patients know hypersensitivity metformin Use metformin previous 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>pancreatic cancer</keyword>
	<keyword>metformin</keyword>
	<keyword>MAPK pathway</keyword>
	<keyword>PI3K/Akt pathway</keyword>
	<keyword>gemcitabine</keyword>
</DOC>